A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug. Nardus Engelbrecht | AP Gilead‘s twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday. The positive phase-three trial data on lenacapavir sets the stage for likely approval by the U.S. Food and Drug Administration for HIV prevention. “Now that we have a comprehensive dataset across multiple study populations, Gilead will work urgently with regulatory, government, public health and community partners to ensure that, if approved, we can deliver twice-yearly lenacapavir for PrEP worldwide, for all those who want or need PrEP,” said Gilead CEO Daniel O’Day in a statement. PrEP or, pre-exposure prophylaxis, is medication taken to prevent getting HIV, according to the Centers for Disease Control and Prevention. Gilead shares climbed more than 1% on Thursday. The company said 99.9% of participants who received lenacapavir did not acquire HIV, with two cases among 2,180 people. The trial included cisgender men, transgender men, transgender women and gender non-binary people who have sex with partners assigned …